SABER Study for Selected Early Stage Breast Cancer

Eligibility Criteria

• 1. Female, ≥ 50 years of age.
• 2. Oncotype or MammaPrint diagnosis results are required prior to the start of treatment
• 3. Histologically confirmed invasive breast cancer.
• 4. Clinical stage T1N0M0.
• 5. Receptor status: Estrogen-Receptor (ER)/Progesterone-Receptor (PR) positive and Human Epidermal Growth Factor Receptor 2 (HER2) negative.
• 6. Unifocal breast cancer.
• 7. Eastern Cooperative Oncology Group (ECOG) 0, 1.
• 8. Ability to undergo MRI.
• 9. Women of child-bearing potential (WOCBP) must agree to use adequate contraception or agree to undergo sexual abstinence prior to study entry and for the duration of study participation. WOCBP must have a negative serum or urine pregnancy test at time of enrollment. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately.
• 10. Ability to understand the investigational nature, potential risks and benefits of the research study and willingness to sign the written informed consent and HIPAA document(s).
• 1. Patients without histologically confirmed invasive breast cancer.
• 2. Patients without Oncotype or MammaPrint diagnosis results at the start of treatment.
• 3. Patients with metastatic disease.
• 4. ECOG 2, 3, 4.
• 5. Patients that are unable to undergo MRI.
• 6. Prior history of radiation to the chest.
• 7. History of collagenous disease (systemic lupus erythematosus, scleroderma, dermatomyositis).
• 8. Any serious medical or psychiatric illness/condition likely in the judgment of the Investigator(s) to interfere or limit compliance with study requirements/treatment.
• 9. Diagnosis of another primary malignancy within the last 5 years with the exception of non-melanoma skin cancer.
• 10. Patients unable to consent, who are pregnant or nursing, or are prisoners.